24591-33-1

Upstream product

• 643-28-7 2-isopropylaniline 
• 88-69-7 2-(1-methylethyl)phenol 
• 77-78-1 dimethyl sulfate 
• 65738-46-7 2-phenyl-1-propyl methyl ether 
• 26307-50-6 4-bromo-2-isopropyl-phenol 
• 64741-01-1 m-chloroperoxybenzoic acid 
• 2944-47-0 o-isopropylanisole 
• 134435-48-6 3-(1-methylethenyl)-4-methoxyphenylethyl acetate 
• 134435-47-5 3-(1-hydroxy-1-methylethyl)-4-methoxyphenylethanol 
• 134435-50-0 (3-Isopropyl-4-methoxy-phenyl)-acetaldehyde 
• 702-23-8 2-(4-Methoxyphenyl)ethanol 
• 39863-70-2 2-(3-isopropyl-4-methoxyphenyl)ethan-1-ol 
• 104-92-7 1-bromo-4-methoxy-benzene 
• 67-63-0 isopropyl alcohol 

Downstream Products

• 13130-23-9 3,5-dibromo-2-methoxybenzoic acid 
• 134435-51-1 (E)-2-(3-Isopropyl-4-methoxy-phenyl)-5,9-dimethyl-deca-4,8-dienenitrile 
• 61494-73-3 12-hydroxy-abieta-8,11,13-trien-3,7-dione 
• 134435-54-4 7-Isopropyl-6-methoxy-1,1,4a-trimethyl-2-phenylsulfanyl-4,4a,10,10a-tetrahydro-1H-phenanthren-9-one 
• 134435-53-3 7-Isopropyl-6-methoxy-1,1,4a-trimethyl-2-phenylsulfanyl-2,3,4,4a,10,10a-hexahydro-1H-phenanthren-9-one 
• 134435-55-5 2-Benzenesulfinyl-7-isopropyl-6-methoxy-1,1,4a-trimethyl-2,3,4,4a,10,10a-hexahydro-1H-phenanthren-9-one 
• 134435-52-2 7-cyano-3-phenylthio-12-methoxyabieta-8,11,13-triene 
• 1244023-66-2 2-[(1S)-2-iodo-6,6-dimethylcyclohex-2-en-1-yl]-1-[4-methoxy-3-(propan-2-yl)phenyl]ethanol 
• 904925-57-1 4-(benzyloxy-2,6-dimethyl-phenyl)-(3-isopropyl-4-methoxy-phenyl)-methanol 
• 31816-31-6 1-(3-Isopropyl-4-methoxiphenyl)-propanon-2 
• 39863-70-2 2-(3-isopropyl-4-methoxyphenyl)ethan-1-ol 
• 31825-29-3 3‐isopropyl‐4‐methoxybenzaldehyde 
• 77012-37-4 (E)-4-(4,8-dimethylnona-3,7-dien-1-yl)-2-isopropyl-1-methoxybenzene 
• 16214-14-5 4-Methoxy-3-isopropylbenzyl chloride 

Relevant academic research and scientific papers

Desymmetric enantioselective reduction of cyclic 1,3-diketones catalyzed by a recyclable p-chiral phosphinamide organocatalyst

The P-stereogenic phosphinamides are a structurally novel skeletal class which has not been investigated as chiral organocatalysts. However, chiral cyclic 3-hydroxy ketones are widely used as building blocks in the synthesis of natural products and bioactive compounds. However, general and practical methods for the synthesis of such chiral compounds remain underdeveloped. Herein, we demonstrate that the P-stereogenic phosphinamides are powerful organocatalysts for the desymmetric enantioselective reduction of cyclic 1,3-diketones, providing a useful method for the synthesis of chiral cyclic 3-hydroxy ketones. The protocol displays a broad substrate scope that is amenable to a series of cyclic 2,2-disubstituted five- and six-membered 1,3-diketones. The chiral cyclic 3-hydroxy ketone products bearing an all-carbon chiral quaternary center could be obtained with high enantioselectivities (up to 98% ee) and diastereoselectivities (up to 99:1 dr). Most importantly, the reactions could be practically performed on the gram scale and the catalysts could be reused without compromising the catalytic efficiency. Mechanistic studies revealed that an intermediate formed from P-stereogenic phosphinamide and catecholborane is the real catalytically active species. The results disclosed herein bode well for designing and developing other reactions using P-stereogenic phosphinamides as new organocatalysts.

Total synthesis of (±)-Scrodentoid A

An efficient total synthesis of scrodentoid A was accomplished starting from a Hagemann's ester and a substituted (2-bromoethyl)benzene. Key reactions in this synthesis include C-alkylation of the Hagemann's ester, 6-endo-Trig cationic cyclization of an enone and Lewis acid promoted isomerization of a cis-fused ketone.

Enantioselective, Lewis Base-Catalyzed Sulfenocyclization of Polyenes

A sulfenium-ion-initiated, catalytic, enantioselective polyene cyclization is described. Homogeranylarenes and ortho-geranylphenols undergo polycyclization in good yield, diastereoselectivity, and enantioselectivity. The stereodetermining step is the generation of an enantiomerically enriched thiiranium ion from a terminal alkene and a sulfenylating agent in the presence of a chiral Lewis basic catalyst. The use of hexafluoroisopropyl alcohol as the solvent is crucial to obtain good yields. The thioether moiety resulting from the reaction can be subsequently transformed into diverse oxygen and carbon functionality postcyclization. The utility of this method is demonstrated by the enantioselective syntheses of (+)-ferruginol and (+)-hinokiol.

Syntheses and evaluation of multicaulin and miltirone-like compounds as antituberculosis agents

Four multicaulin and miltirone-like phenanthrene derivatives were synthesised and evaluated as antituberculosis agents. The crucial step of the synthesis was Pschorr coupling of 4-(3-isopropyl-4-methoxyphenyl)-2-(2-aminophenyl)ethane (13) to give 2-isopro

Total Synthesis of (±)-Taiwaniaquinol F and Related Taiwaniaquinoids

Total synthesis of (±)-taiwaniaquinol F (1a) has been accomplished via an efficient Lewis acid-catalyzed Nazarov-type cyclization of aryldiallylcarbinols (±)-2e derived from safranal 7. The methodology works under mild conditions using only 2 mol % of met

Total syntheses of multicaulins via oxidative photocyclization of stilbenes

The Wittig reaction of 3-isopropyl-4-methoxybenzaldehyde and 2,3-dimethylbenzylphosphonium bromide afforded the corresponding stilbene mixture 16. Oxidative photocyclization of stilbene 16 with iodine facilitated the first total synthesis of 7-isopropyl-6

Metal triflate-catalyzed cyclization of arylvinylcarbinols: Formal synthesis of (±)-dichroanone and (±)-taiwaniaquinone H

A formal synthesis of diterpenoids viz. the taiwaniaquinoids (±)-dichroanone (1a) and (±)-taiwaniaquinone H (1b) possessing an all carbon quaternary stereocenter has been reported. The key step involves a metal triflate-catalyzed cyclization of arylvinylc

NOVEL 6-5 BICYCIC HETEROCYCLIC DERIVATIVE AND MEDICAL USE THEREOF

An object of the present invention is to provide a medicament as a thyroid hormone receptor ligand which is sufficient in drug efficacy and safety, and has the excellent action as a drug. The present invention provides a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof: [wherein [Chemical Formula 2] is a single bond or a double bond; A is -CH2- or -CO-; X, Y, and Z are each independently a nitrogen atom or a carbon atom; R1 is a hydrogen atom or an aralkyl group; R2 is an alkyl group or an aralkyl group, etc.; R3 is a hydrogen atom or an alkyl group, etc.; R4 is a hydrogen atom or an alkyl group; R5 is a hydrogen atom, an alkyl group or a halo lower alkyl group, etc.; R6 is a hydrogen atom or an alkyl group; R7 is a hydrogen atom, etc.; R8 is a hydrogen atom, or an alkyl group, etc.; and E is -NHCO-G-COR12, etc. (wherein G is a single bond or an alkylene group, and R12 is a hydroxy group or an alkoxy group)].

THYROID HORMONE ANALOGUES AND METHODS FOR THEIR PREPARATION

Thyroid hormone analogues are disclosed. Methods of using such analogues and pharmaceutical compositions containing them are also disclosed, as are novel procedures for their preparation.

Proteomimetic compounds and methods

The present invention relates to compounds and pharmaceutical compositions which are proteomimetic and to methods for inhibiting the interaction of an alpha-helical protein with another protein or binding site. Methods for treating diseases or conditions which are modulated through interactions between alpha helical proteins and their binding sites are other aspects of the invention.